SwitchGear Genomics Launches the Largest Collection of Transcription Factor Response Element Reporter Vectors
SwitchGear offers 91 Response Element Reporters for well-studied pathways to LightSwitch product line in addition to collection of 18,000 endogenous human promoter GoClone reporters.
Menlo Park, CA (PRWEB) November 29, 2011
SwitchGear Genomics, Inc., a leading provider of products for studying regulatory elements in the human genome, launched the LightSwitch Synthetic Response Element GoClone reporter constructs for understanding transcription factor activity in living cells. The new reporter collection of nearly 100 response element vectors represents the largest collection of synthetic response element reporter vectors on the market. The collection of synthetic response elements also complements the company’s genome-wide set of 18,000 endogenous human promoter reporter vectors.
The synthetic response element reporters contain repeated motifs of a transcription factor binding site cloned upstream of a minimal promoter and the company’s novel RenSP luciferase gene. These vectors are used in primary screening assays to understand how drug candidates may affect important biological pathways. The response element reporters can also be used as positive controls in biological pathway analysis.
“We are committed to providing the most comprehensive set of reporter assay content, and the LightSwitch Response Element Collection is an important part of that effort,” said Shelley Force Aldred, Ph.D., co-founder and President of SwitchGear Genomics, Inc.,“In addition to our genome-wide promoter and 3’UTR collections, controls, and luciferase assay reagents, we now offer the industry’s most extensive collection of synthetic response element reporters.” Aldred also remarked that the combination of the company’s synthetic reporters with its endogenous reporters provide pharmaceutical researchers with a powerful tool for primary and secondary screening applications.
About SwitchGear Genomics, Inc.:
SwitchGear Genomics, Inc. is a leading provider of products for studying regulatory elements in the human genome. The company has developed a comprehensive approach to generate new insights into gene regulatory networks and allow researchers to efficiently screen entire pathways in living cells. SwitchGear was founded in March 2005 by Dr. Richard Myers, Dr. Nathan Trinklein and Dr. Shelley Force Aldred from Stanford University. For more information about SwitchGear, please visit the company’s website at http://www.switchgeargenomics.com.
SwitchGear Genomics and New England Biolabs Develop New Multiplex Reporter Assay System
SwitchGear and New England Biolabs have collaborated to launch the LightSwitch Dual Assay System that enables unique multiplexed reporter assay screens
MENLO PARK, Calif. and IPSWICH, Mass., Oct. 25, 2011 /PRNewswire/ — SwitchGear Genomics, Inc., a leading provider of products and services for studying regulatory elements in the human genome, announced that they have partnered with New England Biolabs, Inc. (NEB) to create a new dual reporter assay system that leverages the unique advantages of SwitchGear’s LightSwitch™ Luciferase Assay System and NEB’s BioLux® Cypridina Luciferase Assay technology. Combined with a unique genome-wide promoter reporter collection, the LightSwitch Dual Assay System enables unique multiplexing capabilities in cell-based pathway analysis. The system also facilitates studies using cell lines that are difficult to transfect and may require an internal control to normalize variations in transfection efficiency.
The LightSwitch System is a comprehensive reporter assay platform that includes a genome-wide collection of assay-ready GoClone™ human promoter and 3′UTR luciferase reporters combined with the optimized LightSwitch Luciferase Assay reagents. The LightSwitch System uses the newly developed RenSP luciferase reporter gene that has been optimized for maximum brightness and sensitivity. The NEB BioLux Cypridina Luciferase Assay Kit contains the reagents necessary for assaying the activity of the Cypridina Luciferase reporter.
"We are excited to partner with NEB to expand our reporter assay products in new directions," said Nathan Trinklein, Ph.D., CEO and co-founder of SwitchGear Genomics. "By combining our unique technologies, we now offer our customers new capabilities in their reporter assay-based experiments."
"NEB is pleased to be working with SwitchGear to offer the research community increased capabilities and choice in their luciferase-based reporter gene assays," states Dr. Salvatore Russello, Associate Director of Business Development at NEB. "SwitchGear’s range of reporters offers researchers a new way in which to experience the advantages of the Cypridina Luciferase."
About SwitchGear Genomics, Inc.:
SwitchGear Genomics, Inc. is a leading provider of innovative products for studying gene regulation in the human genome. The company has developed a comprehensive approach to generate new insights into gene regulatory networks, allowing researchers to efficiently screen entire pathways in living cells. SwitchGear was founded in March 2005 by Dr. Richard Myers, Dr. Nathan Trinklein and Dr. Shelley Force Aldred from Stanford University. For more information about SwitchGear, please visit the company’s website at www.switchgeargenomics.com
About NEB:
Established in the mid 1970′s, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and six subsidiaries located in Canada, China, France, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com.
SOURCE New England Biolabs
SwitchGear Genomics announces distribution agreement with Cosmo Bio
SwitchGear agreement with Cosmo Bio will allow broader exposure in Japan
MENLO PARK, Calif. – June, 2011 – SwitchGear Genomics Inc., a leading provider of products for studying the regulatory elements in the human genome, today announced that the company signed an agreement for Cosmo Bio Co., LTD to distribute the innovative LightSwitch Luciferase Assay System™ in Japan. The system consists of a complete reporter assay solution including a genome-wide collection of human promoter and 3′UTR luciferase reporters and optimized luciferase assay reagents for measuring transcriptional activation and translational efficiency in living cells.
“We are pleased to be expanding sales in Japan,” said Nathan Trinklein, Ph.D., CEO and co-founder of SwitchGear Genomics, “our agreement further shows our commitment to providing a full and cost-effective reporter assay solution in rapidly growing markets worldwide.”
Under the agreement, Cosmo Bio will promote and sell all components of the LightSwitch Luciferase Assay System in Japan with marketing and technical support from SwitchGear.
About SwitchGear Genomics, Inc.:
SwitchGear Genomics Inc. is a leading provider of technologically innovative products for studying the regulatory elements in the human genome. The company has developed a comprehensive approach to generate new insights into gene regulatory network, allowing researchers to efficiently screen entire pathways in living cells. SwitchGear was founded in March 2005 by Dr. Richard Myers, Dr. Nathan Trinklein and Dr. Shelley Force Aldred from Stanford University. For more information about SwitchGear, please visit the company’s website at www.switchgeargenomics.com
Contact info:
Nathan Trinklein, Ph.D.
CEO and co-founder of SwitchGear Genomics
650-323-6763
SwitchGear Genomics’ LightSwitch Luciferase Assay System identifies functional sequence variants associated with disease
Recent publication highlights that LightSwitch Luciferase Assay System enables researchers to measure the function of hundreds of sequence variants in 3′UTRs and promoters
MENLO PARK, CA. (June 2011) – SwitchGear Genomics, a leading provider of products for studying the regulatory elements in the human genome, today announced the application of its GoClone luciferase reporter products in identifying functional sequence variants that map to expression quantitative trait loci (eQTLs) in a PLoS Genetics article “Identification, Replication, and Functional Fine-Mapping of Expression Quantitative Trait Loci in Primary Human Liver Tissue."
http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1002078
Expression quantitative trait loci (eQTLs) are genomic regions associated with changes in gene expression and are important in understanding the potential link between genetic variants and disease. The researchers in this study sought to identify eQTLs associated with variation in gene expression in human liver tissue.
Their findings revealed that eQTL associations were enriched near proximal promoters and 3′ UTRs. Many of the eQTLs were mapped to a potential causative variant or haplotype, a number of which were functionally validated using SwitchGear’s LightSwitch Luciferase Assay System.
“Our custom variant analysis service using our unique promoter and 3′UTR luciferase reporters helped to establish a functional link between genomic sequence variants and their effect on gene expression," said Nathan Trinklein, CEO and co-founder of SwitchGear Genomics. “Mapping eQTLs associated with expression variation and functionally validating the causative SNPs is an important process for understanding the association between SNPs and disease."
About SwitchGear Genomics, Inc.:
SwitchGear Genomics Inc. is a leading provider of products for studying the regulatory elements in the human genome. The company has developed a comprehensive approach to generate new insights into gene regulatory networks and allow researchers to efficiently screen entire pathways in living cells. SwitchGear was founded in March 2005 by Dr. Richard Myers, Dr. Nathan Trinklein and Dr. Shelley Force Aldred from Stanford University. For more information about SwitchGear, please visit the company’s website at http://www.switchgeargenomics.com
SwitchGear Genomics announces distribution agreement for FuGENE® HD transfection reagent and novel transfection optimization kit
SwitchGear is pleased to offer for direct sale FuGENE HD transfection reagent along with proprietary transfection optimization kit
MENLO PARK, Calif. – January 19, 2011 – SwitchGear Genomics Inc., a leading provider of products for studying the regulatory elements in the human genome, today announced that the company will offer FuGENE® HD transfection reagent as an individual product and as part of its novel LightSwitch Transfection Optimization Kit. SwitchGear has also recently launched the innovative LightSwitch Luciferase Assay System™, a full reporter assay solution including a genome-wide collection of assay-ready GoClone™ human promoter and 3’UTR luciferase reporters and optimized luciferase assay reagents for measuring transcriptional activation and translational efficiency in living cells. The company is also offering FuGENE® HD transfection reagent to complement the product line.
“As a part of SwitchGear’s commitment to providing a complete reporter assay solution, we offer an start-to-finish system that will allow researchers to perform reporter assays quickly and easily without having to do any cloning or reagent optimization,” said Patrick Collins, Ph.D., Director of Research and Development.
SwitchGear has also developed the novel LightSwitch Transfection Optimization Kit utilizing FuGENE® HD. The kit contains everything required to optimize transfection conditions for any cell line and condition of interest. SwitchGear announced a new program entitled “The Transfection Optimization Challenge” where the company has openly invited researchers to use the kit to both optimize their own experiments and receive free GoClone products. Visit http://switchgeargenomics.com/transfection-optimization-challenge/ to learn how to participate in the “Transfection Optimization Challenge.”
About SwitchGear Genomics, Inc.:
SwitchGear Genomics Inc. is a leading provider of technologically innovative products for studying the regulatory elements in the human genome. The company has developed a comprehensive approach to generate new insights into gene regulatory network, allowing researchers to efficiently screen entire pathways in living cells. SwitchGear was founded in March 2005 by Dr. Richard Myers, Dr. Nathan Trinklein and Dr. Shelley Force Aldred from Stanford University. For more information about SwitchGear, please visit the company’s website at www.switchgeargenomics.com
Contact info:
Nathan Trinklein, Ph.D.
CEO and co-founder of SwitchGear Genomics
650-323-6763
SwitchGear Genomics introduces innovative LightSwitch Luciferase Assay System™ for screening gene regulation in living cells
Comprehensive solution for reporter assays includes a genome-wide collection of cloned human promoters and 3’UTRs in a novel luciferase vector that that utilizes an optimized luciferase reagent
MENLO PARK, Calif. – January 12, 2011 – SwitchGear Genomics Inc., a leading provider of products for studying the regulatory elements in the human genome, today announced the launch of the innovative LightSwitch Luciferase Assay System™, a comprehensive reporter assay solution for measuring transcriptional activation and translational efficiency in living cells.
The new SwitchGear LightSwitch system includes a genome-wide collection of assay-ready GoClone™ promoter and 3’UTR luciferase reporters paired with optimized LightSwitch luciferase assay reagents. The GoClone reporter vectors utilize a novel luciferase gene and a unique luciferase reagent specifically developed by SwitchGear to provide industry-leading sensitivity. SwitchGear also offers the highly-efficient FuGENE-HD transfection reagent with its system. This complete reporter assay solution enables researchers to rapidly measure the promoter and 3’UTR activity for any gene in the genome.
“SwitchGear has created an optimized luminescent reporter RenSP by increasing the gene’s overall light output and decreasing the half-life of the reporter protein,” said Nathan Trinklein, Ph.D., co-founder and CEO of SwitchGear Genomics, “We functionally screened thousands of synthetic gene sequence variants with predicted improvements and removed sequence elements that might interfere with expression measurements. The result is a luciferase that is nearly 100% brighter than other luminescent reporter genes and that has been optimized for use with our companion reagents.”
Shelley Force Aldred, Ph.D., co-founder and president of SwitchGear Genomics added, "By providing a fully optimized luciferase system, researches can focus their efforts on doing experiments and analyzing data rather than having to spend time cloning and optimizing reagents and conditions."
About SwitchGear Genomics, Inc.:
SwitchGear Genomics Inc. is a leading provider of innovative products for studying gene regulation in the human genome. The company has developed a comprehensive approach to generate new insights into gene regulatory networks, allowing researchers to efficiently screen entire pathways in living cells. SwitchGear was founded in March 2005 by Dr. Richard Myers, Dr. Nathan Trinklein and Dr. Shelley Force Aldred from Stanford University. For more information about SwitchGear, please visit the company’s website at www.switchgeargenomics.com
Sigma® Life Science and SwitchGear Genomics to Co-develop Simplified Novel microRNA Target Validation System
FORWARD INQUIRIES TO: Sigma-Aldrich
Sarah Bruno
+ (1) 314-286-7810
sarah.bruno@sial.com
MEDIA INQUIRIES: kdm communications limited
Sarah Khan
+44 (0) 1234 210555
ideas@kdm-communications.com
St. Louis, MO. – August 9, 2010 – Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq:SIAL), and SwitchGear Genomics, Inc. today announced a joint project to develop and distribute a novel microRNA (miRNA) target reporter system. Combining SwitchGear Genomics’ expertise with Sigma’s versatile lentiviral technology, these ready-to-use reporter vectors are expected to simplify miRNA target validation, enabling researchers to investigate gene regulation in a variety of biological pathways.
“This is a very exciting joint effort,” said Dr Nathan Trinklein, CEO and co-founder of SwitchGear Genomics. “We believe that combining unique technologies from SwitchGear Genomics with Sigma’s industry-leading lentiviral technology and production capabilities will enable researchers to study miRNA function and gene regulation on an unprecedented scale.”
The genome-wide collection of reporter vectors is expected to provide highly effective miRNA target validation without the need for time-consuming and laborious reporter cloning. Use of Sigma’s patented lentiviral technology is expected to allow the highly regarded SwitchGear GoClone™ miRNA target sets to be used in a broad range of cell types, including primary cells and stem cells.
“We are excited to partner with SwitchGear Genomics on the co-development of this unique vector system,” added Dr. Supriya Shivakumar, Global Commercial Marketing Manager for Functional Genomics at Sigma Life Science. “By offering this novel reporter technology in a lentiviral format we are addressing specific customer needs and we believe we are helping to further fundamental understanding of gene regulation.”
Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as “are expected to,” “we believe,” “is expected to,” or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the miRNA Target Validation System will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of the products from the miRNA Target Validation System will achieve any particular levels of revenue in the future. In particular, management’s expectations regarding the miRNA Target Validation System could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company’s assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich’s current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company’s leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 7,600 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.
About SwitchGear Genomics, Inc: SwitchGear Genomics, Inc. is a leading provider of products for studying regulatory elements in the human genome. The company has developed a comprehensive approach to generate new insights into gene regulatory networks and allow researchers to efficiently screen entire pathways in living cells. SwitchGear was founded in March 2005 by Dr. Richard Myers, Dr. Nathan Trinklein and Dr. Shelley Force Aldred from Stanford University. For more information about SwitchGear, please visit the company’s website at http://switchgeargenomics.com.
Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co. SwitchGear GoClone is a trademark of SwitchGear Genomics, Inc.
SwitchGear Genomics launches novel screening products for profiling miRNA function
Collections of experimentally-validated human 3’UTR reporter vectors empower researchers to screen for miRNA function in cells
MENLO PARK, Calif. – April 1, 2010 – SwitchGear Genomics, Inc., a leading provider of products for studying regulatory elements in the human genome, today announced the launch of a unique research tool for screening for miRNA function in living cells. The new SwitchGear GoClone™ miRNA target sets utilize experimentally-validated luciferase reporter vectors to accurately quantify human 3’UTR activity in response to a number of relevant miRNAs.
“The SwitchGear GoClone™ validated miRNA targets were initially identified using published data and prediction algorithms. The final selection of 3’UTR luciferase constructs were co-transfected with miRNA mimics to assess which 3’UTR targets showed the strongest responses,” said Nathan Trinklein, Ph.D., co-founder and CEO of SwitchGear Genomics, Inc. “We are offering unique miRNA target biomarkers to allow researchers to effectively screen for miRNA function in response to any experimental condition.”
SwitchGear offers the following GoClone™ validated miRNA targets for screening applications for the following miRNAs: mir-21, mir-29a, let-7a, mir-122, mir-124, mir-155, mir-200a, mir-208a, and mir-223. These miRNAs play a range of roles in regulating physiological processes from cholesterol biosynthesis to stem cell differentiation to the regulation of tumorigenesis.
“We performed a screen of predicted miR-122 targets using our collection of 3’UTR luciferase reporters,” said Patrick Collins, Ph.D., Director of Research and Development, “We identified several novel targets for this miRNA which is an important regulator of normal and pathological processes in the liver.” In addition, Collins remarked that the GoClone™ validated miRNA target sets serve as an excellent starting point for researchers who are new to the field of miRNA studies.
About SwitchGear Genomics, Inc.:
SwitchGear Genomics, Inc. is a leading provider of products for studying regulatory elements in the human genome. The company has developed a comprehensive approach to generate new insights into gene regulatory networks and allow researchers to efficiently screen entire pathways in living cells. SwitchGear was founded in March 2005 by Dr. Richard Myers, Dr. Nathan Trinklein and Dr. Shelley Force Aldred from Stanford University. For more information about SwitchGear, please visit the company’s website at http://switchgeargenomics.com.
Contact:
Nathan Trinklein, Ph.D., CEO
SwitchGear Genomics, Inc.
650-323-6570
Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity
Madison, WI (November, 18, 2009) — Promega Corporation and SwitchGear Genomics announce a novel method for characterizing DNA-protein interactions. Results of a study using the HaloCHIP™ System and high-throughput promoter assays demonstrate the ability to correlate DNA binding events to transcriptional activation or repression for the CREB transcription factor. The findings appear in the article “A functional analysis of the CREB signaling pathway using HaloCHIP-chip and high throughput reporter assays“, recently published in BMC Genomics online.
This combination of technologies enables discovery of genome-wide DNA binding sites for transcription factors and the functional activities of the promoter sequences bound by those transcription factors. “This comprehensive approach enables the comparison between binding events and transcriptional activity,” said Nathan Trinklein, Ph.D., co-founder and CEO of SwitchGear Genomics. “Characterizing the functional consequences of binding events is essential to more fully understanding the control of gene expression.”
HaloCHIP, which uses Promega HaloTag® Technology, eliminates the need for antibodies to capture protein:DNA complexes, thereby avoiding one of the major challenges of chromatin immunoprecipitation (ChIP) techniques.
“HaloCHIP allows researchers to more easily and efficiently capture genome-wide protein-DNA complexes starting with a much smaller number of cells,” stated Danette Hartzell, Senior Research Scientist at Promega Corporation. “This antibody-free method for revealing DNA binding events in combination with functional reporter assays can significantly advance gene regulation studies.”
About Promega:
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 14 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.
About SwitchGear Genomics, Inc.:
SwitchGear Genomics Inc. is a leading provider of products for studying the regulatory elements in the human genome. The company has developed a comprehensive approach to generate new insights into gene regulatory networks and allow researchers to efficiently screen entire pathways in living cells. SwitchGear was founded in March 2005 by Dr. Richard Myers, Dr. Nathan Trinklein and Dr. Shelley Force Aldred from Stanford University. For more information about SwitchGear, please visit the company’s website at switchgeargenomics.com
SwitchGear Genomics launches novel high-throughput screening products for profiling biological pathway regulation
Collections of experimentally-validated human promoter reporter vectors empower researchers to measure transcriptional regulation across genes in a variety of different biological pathways
MENLO PARK, Calif. – October 14, 2009 – SwitchGear Genomics, Inc., a leading provider of products for studying regulatory elements in the human genome, today announced the availability of the first cost-effective, high-throughput research tools for screening transcriptional activation and repression in a number of key biological pathways. The new SwitchGear pathway sets utilize experimentally-validated luciferase reporter vectors to accurately quantify human promoter activity from complete sets of genes associated with inflammation, cholesterol biosynthesis, oncology, vascular biology, nuclear hormone receptor signaling, and many other important biological pathways.
"The SwitchGear panels of human promoter targets was selected from our genome-wide reporter collection of promoters using motif analysis and published functional genomic data sets," said Shelley Force Aldred, co-founder and President of SwitchGear Genomics, Inc. "We then performed pathway-specific inductions to create an activity profile across the set of constructs. We offer complete pathway profiling sets of constructs in high-throughput plate formats that empower researchers to efficiently profile the effects of many compounds and conditions." In addition, the company provides a smaller subset of "key responder" promoter constructs that showed a strong induction response in the experiments and which may be used as biomarkers in primary screening applications.
Researchers at the National Institutes of Health screened over 1400 compounds to test hypoxia pathway stimulation and published the results in an article entitled "Identification of Chemical Compounds that Induce HIF-1alpha Activity." The screening process, including the use of the SwitchGear Genomics hypoxia set of promoter reporter assays, differentiated between 3 hypoxia mimetics and 2 other compounds that triggered the pathway independent of HIF-1alpha, a result important for effective compound screening.
In addition to the hypoxia (HIF1a) pathway products, SwitchGear offers the following reporter assay profiling sets in both plate format and biomarker subsets: CREB, NF-kB, heat shock (HSF), p53, STAT, serum response factor (SRF), and cholesterol biosynthesis (SREBP). In addition, the company offers nuclear receptor sets for estrogen receptor, androgen receptor, and glucocorticoid receptor pathways.
About SwitchGear Genomics, Inc.:
SwitchGear Genomics, Inc. is a leading provider of products for studying regulatory elements in the human genome. The company has developed a comprehensive approach to generate new insights into gene regulatory networks and allow researchers to efficiently screen entire pathways in living cells. SwitchGear was founded in March 2005 by Dr. Richard Myers, Dr. Nathan Trinklein and Dr. Shelley Force Aldred from Stanford University. For more information about SwitchGear, please visit the company’s website at http://switchgeargenomics.com.
Contact:
SwitchGear Genomics, Inc.
Brian McKelligon, 650-323-6570
Vice President, Sales and Marketing
brianm@switchgeargenomics.com